This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: SAR and 3D-QSAR studies on thiadiazolidinone derivatives: Exploration of structural requirements for glycogen synthase kinase 3 inhibitors

Title SAR and 3D-QSAR studies on thiadiazolidinone derivatives: Exploration of structural requirements for glycogen synthase kinase 3 inhibitors
Abstract

The 2,4-disubstituted thiadiazolidinones (TDZD) are described as the first ATP-noncompetitive GSK-3 inhibitors. Following an SAR study about TDZD, different structural modifications in the heterocyclic ring aimed to test the influence of each heteroatom on the biological study are here reported here. Various compounds such as hydantoins, dithiazolidindiones, rhodanines, maleimides, and triazoles were synthesized and screened as GSK-3 inhibitors. After an extensive SAR study among these different heterocyclic families, TDZDs have been revealed as a privileged scaffold for the selective inhibition of GSK-3. A CoMFA analysis was also performed highlighting the molecular electrostatic field interaction in the interaction of TDZDs with GSK-3. Moreover, first mapping studies indicate two binding modes which in turn might imply relevant differences in the mechanism that underly the inhibitory activity of TDZDs.

Apa Reference Martinez, A., Alonso, M., Castro, A., Dorronsoro, I., Gelpí, J. L., Luque, F. J., Pérez, C., & Moreno, F. J. (2005). SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives:  Exploration of Structural Requirements for Glycogen Synthase Kinase 3 Inhibitors. Journal of Medicinal Chemistry, 48(23), 7103–7112. 10.1021/jm040895g
Doi 10.1021/jm040895g
Publication Date 8 Oct 2005
Publication Type Article
Researcher Ana Martínez
Ontology Genome Assembly, Drug Discovery and design, Molecular Interactions/Docking
Research Groups Translational Medicinal and Biological Chemistry
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home